Professor Serke, Professor Huhn
Priv.-Doz. Martin, Professor Hoelzer
Dr. Goldschmidt, Professor Haas
HD1 1995

Dr. Cremer, Prof. Ho
„Triple MMM“ 2000

Front-Line Trials of the GMMG

- HD1 Trial: Tandem-Transplantation 1996 – 1998 (Phase II, n=151)
- HD2 Trial: Single- versus Double-Transplantation (Phase III, n=480) 1998 – 2001
- HD3 Trial: Tandem-Transplantation (Germany) plus/minus Thalidomide (Phase III, GMMG n=550, HOVON n=500) 2001 – 2004
- HO65/HD4 Trial: VAD vs. PAD, Transplantation, maintenance Thalidomide vs. Bortezomib (Phase III, GMMG n=399, HOVON=434) 2005-2008
- MM5 Trial: VCD vs. Pad, Standard-intensification, consolidation / maintenance Lenalidomid, maintenance 2a vs. until CR (Phase III, n=504, start II/2010)

HD-1:Treatment Plan



1996-1998 (n=151)

Berlin	Serke/Huhn
Frankfurt	Martin/Hoelzer
Heidelberg	Goldschmidt/Haas

HD2 Therapy Plan

Randomisation VID vs. VAD

until CR or plateau, max. 6 cycles

HD-cyclophosphamide (ifosfamide) + G-CSF

1998-2001 (n=485)

Leukaphereses
CD34⁺-selection optional

Randomisation

Melphalan 200 mg/m² + PBSCT

cycle 1

cycle 2

interferon-α

One cycle

interferon-α

HD3/HOVON50-Studie 2001-2004



HOVON 65 MM / GMMG-HD4 Trial



HO65/HD4: Impact of kidney function



C. Scheid et al., ASH 2010 / EBMT 2011

Comparison between both study arms HD4 Deletion 17p13



PAD (Vel/Dex) zur Erstlinienbehandlung von Patienten mit multiplen Myelom

„Standard für die Induktionstherapie war bislang VAD, so dass der Ersatz der ohnehin nicht sehr wirksamen Substanz Vincristin durch Bortezomib entsprechend dem GMMG/HOVON-Protokoll als neuer Standard für die Induktionstherapie anzusehen ist. Dies entspricht auch der Bewertung der deutschen Studien-gruppe GMMG.“

MDK Gutachten Prof. Heyll, August 2009

MM5-Trial



1) High Risk Patients, optional in Phase II trial

GMMG-ReLApsE study



1) stem cell collection only if no useable stem cells are available from earlier mobilization
2) Lenalidomide (Revlimid®) maintenance therapy 10mg/day
R-Lenalidomide (Revlimid®), D-Dexamethasone, HD Mel-high dose Melphalan

GMMG-HD2, -HD3, -HD4 – Beteiligte Kliniken und Praxen